Ramesh Amin
Psychiatry · Conyers, GANPI 1427037514
Payments from drug & device makers
Across 130 payments — averaging $18.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$460
- Neurocrine Biosciences, Inc.$443
- AbbVie$279
- Indivior Inc.$276
- Otsuka America Pharmaceutical, Inc.$248
- Alkermes, Inc.$247
- plus $479 from 8 others
Across 1 payment — averaging $125.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Indivior Inc.$125
What the payments were for
- Food & beverage$2,33896%
- Education$944%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 32 | $460 |
| Neurocrine Biosciences, Inc. | 20 | $443 |
| AbbVie(2 entities) | 17 | $279 |
| Indivior Inc. | 17 | $276 |
| Otsuka America Pharmaceutical, Inc. | 12 | $248 |
| Alkermes, Inc. | 9 | $247 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $175 |
| Vanda Pharmaceuticals Inc. | 6 | $114 |
| Lundbeck LLC | 5 | $96 |
| Eisai Inc. | 1 | $35 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Novo Nordisk | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Noven Therapeutics, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$480
- ARISTADA INITIO$120
How this compares
$2,433 in reported general payments places this provider in the 75th percentile of 900 psychiatry providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega TrinzaPaliperidone Palmitate | 42 | $383,899 |
| IngrezzaValbenazine Tosylate | 34 | $269,611 |
| Invega SustennaPaliperidone Palmitate | 78 | $269,172 |
| Divalproex Sodium ErDivalproex Sodium | 154 | $7,220 |
| Clozapine | 60 | $5,699 |
| Quetiapine Fumarate | 132 | $5,106 |
| Risperidone | 303 | $3,478 |
| Chlorpromazine Hcl | 15 | $3,368 |
| Aripiprazole | 26 | $3,323 |
| Ziprasidone Hcl | 64 | $3,116 |
| Paliperidone ErPaliperidone | 14 | $2,329 |
| Olanzapine | 70 | $1,977 |
| Fluvoxamine Maleate | 37 | $1,824 |
| Trazodone Hcl | 116 | $1,448 |
| Haloperidol Decanoate | 31 | $1,425 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Trinza, Invega Sustenna | $460 | $653,071120 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $443 | $269,61134 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 900 psychiatry providers in Georgia.
Other psychiatry in Conyers
- Robert RiesenbergAtlanta$51.1M
- Saundra Maass-RobinsonAtlanta$11.1M
- David PurselleAtlanta$7.4M
- Maria JohnsonDecatur$5.4M
- Bethany DavisAtlanta$4.4M
- Michael BanovMarietta$4.2M
- Michael MobleySavannah$2.9M
- Richard PettyLoganville$2.9M
- Felipe SuplicyRome$2.3M
- Angelo SambunarisAlpharetta$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.